Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Other

Revive Therapeutics primes the pump on Bucillamine

By The Northwire Desk — AI Analysis Dec 15, 2025 · 17:09 RVV · 0.015 Revive Therapeutics Ltd
RVV · Price

Executive Summary

  • Revive Therapeutics Ltd. provided an update on its collaborative research study with Defence R&D Canada (DRDC) evaluating Bucillamine as a potential treatment for nerve agent-induced brain injury.
  • The study is expected to conclude with results in January 2026.
  • Any findings from the study will be released only with the express authorization of DRDC.

Key Details

  • Study Subject: Evaluation of Bucillamine as a potential treatment for nerve agent exposure.
  • Collaborator: Defence R&D Canada -- Suffield Research Centre (DRDC), an agency within the Canadian Department of National Defence.
  • Study Status: The research is ongoing and expected to conclude in January 2026.
  • Data Release Protocol: Findings will be released only with the express authorization of DRDC.
  • Company Focus: Revive Therapeutics is a life sciences company focused on R&D for infectious diseases and medical countermeasures, leveraging U.S. government regulatory incentives.

Notable Quotes

  • "After recent discussions with the DRDC, the research study on Bucillamine is expected to conclude with results in January, 2026."
  • "Any findings from the study will be released only with the express authorization of DRDC."
Read the original news release →

More from Revive Therapeutics Ltd

Jun 26, 2026 · 16:15

Cash-burning micro-cap biotech raises survival capital via dilutive private placement while pursuing repurposed drug for nerve agents and infectious diseases.

Financings May 20, 2026 · 07:45

Revive Therapeutics Patents Fuel Defense Strategy Amidst Price Consolidation

M&A / Property Mar 11, 2026 · 17:34

Revive Therapeutics advances bucillamine patents

M&A / Property Mar 11, 2026 · 07:30

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

M&A / Property Dec 15, 2025 · 07:30

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Other Nov 21, 2025 · 16:56

Revive talks DRDC study on bucillamine for nerve agents

Other